Effects of MDMA on Complex Brain Function in Laboratory Animals

Ali, 1990, Oral administration of MDMA produces selective, serotonergic neurotoxicity in rodents and nonhuman primates, SAAS Bull. Biochem. Biotech., 3, 48 Ali, 1993, Oral administration of 3,4-Methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletions in the nonhuman primate, Neurotoxic. Teratol., 15, 91, 10.1016/0892-0362(93)90067-X Battaglia, 1998, MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons., Pharmac. Biochem. Behav., 29, 269, 10.1016/0091-3057(88)90155-4 Bilsky, 1991, MDMA produces a conditioned place preference and elicits ejaculation in male rats: A modulatory role for the endogeneous opioids, Pharmac. Biochem. Behav., 40, 443, 10.1016/0091-3057(91)90577-O Bilsky, 1990, Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of alcoholic beverage., Pharmac. Biochem. Behav., 37, 633, 10.1016/0091-3057(90)90538-S Bilsky, 1991, MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference, Pharmac. Biochem. Behav., 39, 509, 10.1016/0091-3057(91)90217-P Bradberry, 1994, Microdialysis assessment of the impact of (+)3,4-methylenedioxymethamphetamine, cocaine, and cocaethylene on serotonergic neurons, Drug Dev. Res., 33, 1, 10.1002/ddr.430330102 Bronson, 1994, Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives, Drug Alcohol Dep., 36, 161, 10.1016/0376-8716(94)90141-4 Callahan, 1988, Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline, J. Pharmac. Exp. Ther., 246, 866 Callaway, 1992, Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat, Eur. J. Pharmac., 214, 45, 10.1016/0014-2999(92)90094-K Callaway, 1992, Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist, J. Pharmac. Exp. Ther., 263, 318 Commins, 1987, Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain, J. Pharmac. Exp. Ther., 241, 338 Doran, 1991, The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat, Pharmac. Biochem. Behav., 39, 813, 10.1016/0091-3057(91)90171-W Finnegan, 1988, Orally administered MDMA causes a long-term depletion of serotonin in the rat brain, Brain Res., 447, 141, 10.1016/0006-8993(88)90974-2 Frederick, D.L.; Gillam, M.P.; Allen, R.R.; Paule, M.G. Acute effects of methylenedioxymethamphetamine (MDMA) on several complex brain functions in monkeys. Pharmac. Biochem. Behav. in press, 1996a. Frederick, D.L.; Ali, S.F.; Slikker, W., Jr.; Gillam, M.P.; Allen, R.R.; Paule, M.G. Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neurotoxic. Teratol. in press, 1996b. Glennon, 1992, Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline, Pharmac. Biochem. Behav., 43, 759, 10.1016/0091-3057(92)90405-5 Glennon, 1987, The effect of MDMA (“Ecstasy”) and its optical isomers on schedule-controlled responding in mice, Pharmac. Biochem. Behav., 26, 425, 10.1016/0091-3057(87)90141-9 Gold, 1989, A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA, Psychopharmacology, 99, 40, 10.1007/BF00634450 Gold, 1988, Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats, J. Pharmac. Exp. Ther., 247, 547 Goudie, A.J.; Demellweek, C. Conditioning factors in drug tolerance. In: Goldberg, S.R.; Stolerman, I.P., eds. Behavioral Analysis of Drug Dependence. New York: Academic Press; 1986:225–285. Greer, 1985, Using MDMA in psychotherapy, Advances, 2, 57 Greer, 1986, Subjective reports of the effects of MDMA in a clinical setting, J. Psychoactive Drugs, 18, 319, 10.1080/02791072.1986.10472364 Grob, 1994, MDMA research update: The Harbor-UCLA project, Newsletter of the Multidisciplinary Assoc. for Psychedelic Studies, IV, 2 Gudelsky, 1994, Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists, Eur. J. Pharmac., 264, 325, 10.1016/0014-2999(94)90669-6 Hubner, 1988, The threshold lowering effects of MDMA (ecstacy) on brain-stimulation reward, Psychopharmacology, 95, 49, 10.1007/BF00212765 Insel, 1989, 3,4-Methylenedioxymethamphetamine (“Ecstasy”) selectively destroys brain serotonin terminals in rhesus monkeys, J. Pharmac. Exp. Ther., 249, 713 Kamien, 1986, The effects of (±)-methylenedioxymethamphetamine and (±)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline, Drug Alcohol Depend., 18, 139, 10.1016/0376-8716(86)90046-3 Kehne, 1992, Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats, J. Pharmac. Exp. Ther., 260, 78 Krasnegor, N.A. (ed.). Behavioral Tolerance: Research and Treatment Implications. NIDA Res. Monogr. Ser. 18; 1978. Krystal, 1992, Chronic 3,4-Methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function, Am. J. Drug Alcohol Abuse, 18, 331, 10.3109/00952999209026070 Lawn, 1985, Schedules of controlled substances: Temporary placement of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I, Fed. Regist., 50, 118–23 Leonardi, 1994, MDMA (ecstasy) inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac), Neuropsychopharmacology, 10, 231, 10.1038/npp.1994.26 LeSage, 1993, MDMA and memory: The acute and chronic effects of MDMA in pigeons performing under a delayed-matching-to-sample procedure, Psychopharmacology, 110, 327, 10.1007/BF02251288 Li, 1989, Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats, Pharmac. Biochem. Behav., 33, 641, 10.1016/0091-3057(89)90402-4 Liester, 1992, Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use, J. Nervous Mental Disease, 180, 345, 10.1097/00005053-199206000-00001 Lin, 1993, Comparison of conditioned taste aversions produced by MDMA and d-amphetamine, Pharmac. Biochem. Behav., 46, 153, 10.1016/0091-3057(93)90333-O Lin, 1994, Contrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions, Pharmac. Biochem. Behav., 47, 369, 10.1016/0091-3057(94)90025-6 Lorens, S.A.; Hata, N.; Cabrera, T. Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and fenfluramine. NIDA Res. Monogr. 95; 1989. Lorens, S.A.; Hata, N.; Cabrera, T.; Hamilton, M.E. Behavioral effects of 5,7-DHT and MDMA treatment in rats. In: Paoletti, R.; Van Houtte, P.M.; Brunello, N.; and Maggi, F.M., eds. Serotonin from Cell Biology to Pharmacology and Therapeutics. Dordrecht, The Netherlands: Kluwer Academic; 1990:615–623. Mansbach, 1989, Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxymethamphetamine (MDEA) in the rat, Eur. J. Pharmac., 167, 49, 10.1016/0014-2999(89)90746-2 McKenna, 1990, Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”), J. Neurochem., 54, 14, 10.1111/j.1471-4159.1990.tb13277.x McKim, W.A. Drugs and Behavior: An introduction to behavioral pharmacology. Englewood Cliffs, New Jersey: Prentice-Hall; 1986:161–185. Miczek, 1994, Psychomotor stimulant effects of d-amphetamine, MDMA and PCP: Aggressive and schedule-controlled behavior in mice, Psychopharmacology, 115, 358, 10.1007/BF02245077 Nader, 1989, Behavioral effects of (±) 3,4-methylenedioxyamphetamine (MDA) and (±) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: Interactions with noradrenergic and serotonergic systems, Psychopharmacology, 98, 183, 10.1007/BF00444689 Nichols, 1986, Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Enactogens, J Psychoactive Drugs, 18, 305, 10.1080/02791072.1986.10472362 Oberlender, 1988, Drug discrimination studies with MDMA and amphetamine, Psychopharmacology, 95, 71, 10.1007/BF00212770 Paulus, 1992, The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity, Neuropsychopharmacology, 7, 15 Peroutka, S.J. Recreational use of MDMA. In: Peroutka, S.J., ed. Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Press; 1990:53–62. Rattray, 1991, Ecstasy: Towards an understanding of the biochemical basis of the actions of MDMA, Essays Biol., 26, 77 Rempel, 1993, Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release, Neuropsychopharmacology, 8, 201, 10.1038/npp.1993.22 Ricaurte, 1985, Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals, Science, 229, 986, 10.1126/science.4023719 Ricaurte, 1988, Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration, Brain Res., 446, 165, 10.1016/0006-8993(88)91309-1 Ricaurte, 1988, (±) Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates, JAMA, 260, 51, 10.1001/jama.260.1.51 Ricaurte, 1993, 3,4-Methylenedioxymethamphetamine, serotonin and memory, J. Pharmac. Exp. Ther., 266, 1097 Robinson, 1993, Effects of cortical serotonin depletion by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade, Neuropsychopharmacology, 8, 77, 10.1038/npp.1993.9 Romano, 1994, MDMA enhances associative and nonassociative learning in the rabbit, Pharmac. Biochem. Behav., 47, 289, 10.1016/0091-3057(94)90012-4 Schechter, 1986, Discriminative profile of MDMA, Pharmac. Biochem. Behav., 24, 1533, 10.1016/0091-3057(86)90480-6 Schechter, 1989, Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”), Pharmac. Biochem. Behav., 31, 817, 10.1016/0091-3057(88)90390-5 Schechter, 1991, Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination, Pharmac. Biochem. Behav., 38, 539, 10.1016/0091-3057(91)90010-Y Schulze, 1988, Acute effects of Δ-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operatnt tests, J. Pharmac. Exp. Ther., 245, 178 Seiden, 1993, Behavioral consequences of partial monamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology, Nat. Instit. Drug Abuse Res. Monogr. Ser., 136, 34 Slikker, 1988, Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA), Toxic. Appl. Pharmac., 94, 448, 10.1016/0041-008X(88)90285-2 Slikker, 1989, Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate, Neurotoxicology, 10, 529 Slikker, W., Jr.; Paule, M.G.; Broening, H.W. The role of the serotonergic systems in behavioral toxicity. In: Chang, L.; Slikker, W., Jr, eds. Neurotoxicology: Approaches and methods. San Diego, CA: Academic Press; 1995:371–380. Spanos, 1989, Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat, Pharmac. Biochem. Behav., 32, 83, 10.1016/0091-3057(89)90044-0 St. Omer, 1991, Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats, Neurotoxic. Teratol., 13, 13, 10.1016/0892-0362(91)90022-O Teitler, 1990, Receptor pharmacology of MDMA and related hallucinogens, Ann. N.Y Acad. Sci., 600, 626, 10.1111/j.1749-6632.1990.tb16915.x Thompson, 1987, Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys, Pharmac. Biochem. Behav., 26, 401, 10.1016/0091-3057(87)90136-5 Zacny, 1990, Tolerance and cross tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine, Pharmac. Biochem. Behav., 35, 637, 10.1016/0091-3057(90)90301-W